Patent EP0169016A2 successfully refreshed from Google Patents.
EP0169016A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Polypeptide cartilage-inducing factors found in bone
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1985-07-08
•
Granted: —
•
Expires: 2005-07-08
Abstract
Abstract Two polypeptide factors that are found in bone and that have chondrogenic/osteogenic activity and TGF- beta activity are described. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each reduces to a single polypeptide indicating that the factors are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF- beta , whereas the other has an N-terminal sequence that is different from that of TGF- beta derived from human placenta. The two factors are purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.
Inventors
- 👤 Saeid Seyedin
- 👤 Thomas Thomas
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 17:03
CPC Classifications
B; B64; B64C; B64C11/00; A; A61; A61K; A61K35/00; A61K35/12; A61K35/32; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; B65; B65B; B65B35/00; B65B35/30; B65B35/50; B65H; B65H31/00; B65H31/30; B65H31/3009; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84; Y10S530/841; Y10S623/00; Y10S623/924; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
51 words
A polypeptide cartilage-inducing factor and substantial equivalents thereof characterized in that the factor: (a) is found in mammalian bone: (b) is a co-factor for inducing cartilage formation; (c) has activity in the TGF-B assay; and (d) is a dimer having an approximate molecular weight of 26,000 daltons as determined by SDS-PAGE.
Claim 2
Dependent Claim
51 words
A polypeptide cartilage-inducing factor and substantial equivalents thereof characterized in that the factor: (a) is found in mammalian bone: (b) is a co-factor for inducing cartilage formation; (c) has activity in the TGF-B assay; and (d) is a dimer having an approximate molecular weight of 26,000 daltons as determined by SDS-PAGE.
Claim 3
Dependent Claim
14 words
The factor of claim 1 further characterized in that the bone is bovine bone.
Claim 4
Dependent Claim
22 words
The factor of claim 1 or 2 further characterized in that each chain of the dimer has the following N-terminal sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser(Ser)Thr-Glu-Lys-Asn--Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu--Gly-Trp-.
Claim 5
Dependent Claim
22 words
The factor of claim 1 or 2 further characterized in that each chain of the dimer has the following N-terminal sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Glu-Asp-Asn--Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu--Gly-Trp-.
Claim 6
Dependent Claim
22 words
An implant composition for inducing chondrogenesis/osteogenesis characterized in that it contains at least one factor of claim 1, 2, 3, or 4.
Claim 7
Dependent Claim
31 words
An implant composition for promoting connective tissue deposition characterized in that it contains at least one factor of claim 1, 2, 3, or 4 free of any activating agent or co-factor.
Claim 8
Dependent Claim
32 words
A composition for promoting proliferation of normal animal cells characterized in that it contains (a) at least one factor of claim 1, 2, 3, or 4; and (b) a TGF-B activating agent.
Claim 9
Dependent Claim
121 words
A process for isolating the factor of claim 1 from bone characterized by the following steps: (a) treating demineralized bone with a chaotropic extractant that solubilizes nonfibrous proteins: (b) subjecting the extract from step (a) to gel filtration to recover a fraction containing proteins of molecular weight 10,000-40.000 daltons; (c) adsorbing the fraction from step (b) onto a carboxymethyl cellulose cation exchanger at approximately pH 4.5-5.5 under denaturing conditions: (d) eluting the adsorbed fraction from the cation exchanger with a sodium chloride gradient; (e) subjecting the portion of the eluate of (d) that elutes at approximately 150 to 250 mM sodium chloride to RP-HPLC or a nondenaturing gel electrophoresis: and (f) recovering said factor from the RP-HPLC or nondenaturing gel electrophoresis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.